EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›VNRX

VNRX

VOLITIONRX LTD

Next earnings Aug 12, 2026 · consensus $-0.60 EPS, $486K rev

Last earnings -6.8% on 2026-05-14

Avoid
$1.28
▼ -0.78%
$1.28▼ -92.56%
over 1Y
L $1.21EODHDH $17.36
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.8%
1W-4.5%
1M-56.5%
3M-67.4%
YTD-76.6%
1Y-92.6%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Avoid
Quality
F
Valuation
Fair value
Filings
Flagged
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy

Revenue grew 40.0% YoY; but unprofitable (net margin -1352.2%).

Revenue (FY2025) $1.73M · FY2025

VOLITIONRX LTD shows $1.73M in FY2025 revenue (+40.0% YoY), a -1352.2% net margin.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$90.0K$306K$775K$1.23M$1.73M
Gross profit—————
Operating income-$28.3M-$31.8M-$36.0M-$27.0M-$21.7M
Net income-$27.0M-$30.6M-$35.7M-$27.0M-$23.4M
Diluted EPS——-$0.50-$0.31—
Net margin-29977.0%-9986.7%-4601.7%-2186.3%-1352.2%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$208M
EV / EBITDA—
EV / Sales120.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-11.5%
FCF yield-9.7%

Quality & risk

ROIC (est.)—
Free cash flow-$19.8M
Total debt$6.71M
Net cash-$5.59M
Altman Z-Score-60.35 distress
Piotroski F-Score2/8

Capital returns

Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+64.2%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Red flag in recent filings — restated periodic report (2026-04-30). Worth a closer look.
  1. 8-K Unregistered share sales2026-06-18
  2. 8-K Material agreement2026-06-10
  3. DEF 14A Proxy statement2026-06-02
  4. 8-K Material agreement2026-05-22
  5. 8-K Officer / director change2026-05-15
  6. 8-K Earnings results2026-05-14
  7. 10-Q Quarterly report2026-05-14
  8. 10-K/A Restated periodic report2026-04-30
  9. 8-K Material event2026-04-28

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-172026-06-18open ↗8-KPeriod ending 2026-06-072026-06-10open ↗424B5Filing2026-06-09open ↗424B5Filing2026-06-05open ↗DEF 14APeriod ending 2026-07-172026-06-02open ↗8-KPeriod ending 2026-05-212026-05-22open ↗8-KPeriod ending 2026-05-122026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗PRE 14APeriod ending 2026-05-122026-05-13open ↗10-K/APeriod ending 2025-12-312026-04-30open ↗

Quality score

F
ValueGrowthProfitHealthMom.
ValueF
GrowthA
ProfitabilityF
Financial healthF
Momentum—
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✓Liabilities below 2× equity
Revenue
$1.73M
+40.0% YoY
Net margin
-1352.2%
ROE
—
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$1.73M+40.0%
Net income-$23.4M+13.4%
Operating income-$21.7M+19.6%
Diluted EPS-$0.31+38.0%
Cash & equivalents$1.12M-65.8%
Total assets$6.90M-26.6%
Total liabilities$42.5M+19.7%
Stockholders' equity-$34.2M-37.5%
Op.: -1258.5%L/E: -1.24x

Frequently asked

Is VOLITIONRX LTD (VNRX) a buy?
VNRX currently carries a Avoid rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 40.0% YoY; but unprofitable (net margin -1352.2%).
What is VOLITIONRX LTD's quality score?
VNRX scores 35.29411764705882/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000093314, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:25:17 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-03-17-05:00
Forterre Gael
Chief Commercial Officer
Tax5.25K @ $0.19$997.69
2026-03-17-05:00
Rootsaert Rodney Gerard
Secretary
Tax3.95K @ $0.19$750.12
2026-03-17-05:00
Micallef Jacob Vincent
Chief Scientific Officer
Tax5.31K @ $0.19$1.01K
2026-03-17-05:00
Plummer Nicholas
GC - Volition Diagnostics
Tax7.00K @ $0.19$1.33K
2026-03-01-05:00
Rootsaert Rodney Gerard
Secretary
Tax3.32K @ $0.21$707.37
2026-03-01-05:00
Forterre Gael
Chief Commercial Officer
Tax2.28K @ $0.21$486.28
2026-03-01-05:00
Plummer Nicholas
GC - Volition Diagnostics
Tax5.87K @ $0.21$1.25K
2026-02-26-05:00
Forterre Gael
Chief Commercial Officer
Award149K

Earnings history

beat/miss · move
2026-05-14Miss -32.1% est▼ -6.78%8-K ↗
2026-03-31Miss -32.1% est▲ +6.32%8-K ↗
2025-11-13Miss -11.4% est▼ -4.37%8-K ↗
2025-10-14Miss -11.4% est▲ +1.77%8-K ↗
2025-08-14Miss -17.6% est▲ +3.84%8-K ↗
2025-05-15—▼ -3.61%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street AnalystsBullish
finance.yahoo.com· 2026-05-24
VolitionRx anticipates first DETECSEPS patient in September as Q1 revenue rises to about $1MBullish
seekingalpha.com· 2026-05-15
VolitionRx anticipates France routine Nu.Q Cancer use by Q4 2026 while targeting 25%-30% 2026 cash OpEx reductionBearish
seekingalpha.com· 2026-04-01
Volition's Capture-Seq Shows Over 95% Detection Of Early-Stage Cancers; Stock UpBullish
nasdaq.com· 2026-03-25
VolitionRx secures $2M financing through amended securities agreement; shares upBullish
seekingalpha.com· 2026-01-08
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of SepsisBullish
finance.yahoo.com· 2025-12-04

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score35 vs 67
Revenue growth40.0% vs 7.1%
Net margin-1352.2% vs 10.5%
Return on equity— vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 2d
Bullish
+0.17
vs typical · 2 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.